NeuroPace, Inc. (NPCE) vs Sight Sciences, Inc. (SGHT)
- NeuroPace, Inc. NPCE 12.47 −1.73%
- Sight Sciences, Inc. SGHT 10.04 +2.87%
NeuroPace, Inc. and Sight Sciences, Inc. are both Medical Devices companies. Sight Sciences, Inc. is the larger, with a market value of $537.7M against $435.6M — 1.2× the size. Sight Sciences, Inc. grew revenue faster over the last twelve months: 16.2% against 11.6%. NeuroPace, Inc. has the higher net margin (−19.3% vs −32.1%) and the higher return on invested capital (−44.6% vs −127.8%). Across the 18 metrics below, NeuroPace, Inc. leads on 11 and Sight Sciences, Inc. on 7.
Valuation
Profitability
| Metric | NPCE | SGHT | Medical Devices median |
|---|---|---|---|
| Gross margin | 81.57% | 87.74% | 57.76% |
| Operating margin | (13.87%) | (29.52%) | (15.07%) |
| Net margin | (19.34%) | (32.13%) | (14.45%) |
| Free cash flow margin | (11.75%) | (19.13%) | (3.88%) |
| Return on equity | (122.05%) | (50.07%) | (10.35%) |
| Return on assets | (18.82%) | (25.68%) | (17.26%) |
| Return on invested capital | (44.64%) | (127.79%) | (5.27%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack